Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon May 31, 2024 12:23pm
124 Views
Post# 36066485

RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

I like your detail.
My assumption, in comparison ONCs Pelareorep has at most flu like symptoms as side effects.
And yes " safe & well lollerated", The IV administration finds the cancer.
Making Pelareorep very unique. It does not have to be administered to the tumour.
it only replicates in a cancer cell(s).
That activity , as they say turns cold tumours hot...
Whst does that mean & benefits.
One proven cancer treatment, long term issue.
The cancer cells disguise themselves as our own. Then our imune system ignores.
AkA a cold tumour.
The Pela activity , lights up the tumour allowing our imune system to function.
Addtionally, many of the in- place top tier treatments only work on a small % of people, because of the hidden, issue.
The addition of Pela can expand that market. Again, thst is one of the considerstions of the existing trials.
Simple language.
As a cotherapy increases the number of utilization & as such an incresse in sucsess.
Anyone who has been though personally or watching cancer.
The chemo works at first. Then after a period of time the cancer comes back, faster & stronger.
As I mentioned previously, many in my family have died of cancer.
My one aunt. Had her 5 years, cancer free. Rang the bell etc etc.
Around yr 10, cancer returned. She died in a few months.
Point.
Everone has cancer cells on & off at all times. Our imune system fights them.
Pelareorep, helps our imune system find the tumours.
AkA a systemic vaccination.
it primes the immune system.
That is the most recent outcomes , being brought before FDA , to be included in phase 3 trial.
 

<< Previous
Bullboard Posts
Next >>